Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report) have been assigned an average rating of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 […]
Macroview Investment Management LLC acquired a new position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,750 shares of the biotechnology company’s stock, valued at approximately $33,000. Several […]
Eversept Partners LP increased its position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) by 13.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,200,999 shares of the biotechnology company’s stock after acquiring an additional 265,174 shares during the quarter. Seres […]
Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) has received an average rating of “Hold” from the seven ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The […]
StockNews.com lowered shares of Seres Therapeutics (NASDAQ:MCRB – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Monday. MCRB has been the topic of a number of other research reports. Canaccord Genuity Group increased their price target on Seres Therapeutics from $11.00 to $15.00 and gave […]